title: Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.
abstract: In much of medical oncology, including neuro-oncology, there is great interest to evaluate the therapeutic potential of immune-based therapies including vaccines, adoptive T cell strategies and modulators of immune checkpoint regulators such as cytotoxic T lymphocyte antigen 4 and programmed death 1. Immune-based treatments exert an indirect anti-tumor effect by generating potent, tumor-targeting immune responses. Robust anti-tumor immune responses have been shown to achieve encouraging radiographic responses across the spectrum of applied immunotherapeutics which are felt to be indicative of a bona fide anti-tumor effect. Conversely, worsening of imaging findings, particularly early in the course of immunotherapy administration, can be challenging to interpret with growing evidence demonstrating that at least a subset of such patients ultimately will derive meaningful clinical benefit. The immune related response criteria were generated to provide guidance regarding the interpretation of such complex imaging findings, for general medical oncologists prescribing immunotherapeutics. An analogous effort that addresses challenges associated with imaging assessment and incorporates nuances associated with neuro-oncology patients is underway and is referred to as the immunotherapy response assessment in neuro-oncology criteria.
authors.affiliation: Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana-2134, Boston, MA, 02215, USA, david_reardon@dfci.harvard.edu.
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Hideho
authors.initials: H
authors.lastname: Okada
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000145:classification / Q000379:methods*; D017063:Outcome Assessment, Health Care; D016896:Treatment Outcome